These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23924436)

  • 1. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.
    Kamikawaji S; Ito G; Sano T; Iwatsubo T
    Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the autophosphorylation sites of LRRK2.
    Kamikawaji S; Ito G; Iwatsubo T
    Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2.
    Gloeckner CJ; Boldt K; von Zweydorf F; Helm S; Wiesent L; Sarioglu H; Ueffing M
    J Proteome Res; 2010 Apr; 9(4):1738-45. PubMed ID: 20108944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
    Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation.
    Ohta E; Kawakami F; Kubo M; Obata F
    Biochem Biophys Res Commun; 2013 Jan; 430(2):560-6. PubMed ID: 23220480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
    Ito G; Okai T; Fujino G; Takeda K; Ichijo H; Katada T; Iwatsubo T
    Biochemistry; 2007 Feb; 46(5):1380-8. PubMed ID: 17260967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 I2020T mutation is associated with tau pathology.
    Ujiie S; Hatano T; Kubo S; Imai S; Sato S; Uchihara T; Yagishita S; Hasegawa K; Kowa H; Sakai F; Hattori N
    Parkinsonism Relat Disord; 2012 Aug; 18(7):819-23. PubMed ID: 22525366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
    Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
    Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.
    Vancraenenbroeck R; Lobbestael E; Weeks SD; Strelkov SV; Baekelandt V; Taymans JM; De Maeyer M
    Biochim Biophys Acta; 2012 Mar; 1824(3):450-60. PubMed ID: 22251894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
    Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
    J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
    Sancho RM; Law BM; Harvey K
    Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.
    Li X; Moore DJ; Xiong Y; Dawson TM; Dawson VL
    J Biol Chem; 2010 Sep; 285(38):29569-76. PubMed ID: 20595391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations.
    Ohta E; Kawakami F; Kubo M; Obata F
    FEBS Lett; 2011 Jul; 585(14):2165-70. PubMed ID: 21658387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.